Nuvaxovid, a COVID-19 vaccine developed by Novavax, has become the fifth COVID-19 vaccine authorised for use in the European Union (EU). Following rigorous safety, efficacy and quality testing by the European Medicines Agency (EMA), the European Commissions has granted a conditional marketing authorization (CMA) of the vaccine for its perceived benefits in providing protection against severe COVID-19 disease.
पूरा बयान पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:
European Commission authorises fifth safe and effective vaccine against COVID-19